The presence of wild type p53 in hematological cancers improves the efficacy of combinational therapy targeting metabolism - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Oncotarget Année : 2015

The presence of wild type p53 in hematological cancers improves the efficacy of combinational therapy targeting metabolism

Résumé

Manipulation of metabolic pathways in hematological cancers has therapeutic potential. Here, we determined the molecular mechanism of action of the metabolic modulator dichloroacetate (DCA) in leukemic cells. We found that DCA induces the AMP-activated protein kinase (AMPK)/p53 pathway with increased efficacy in tumors expressing wild type (wt p53). Clinically relevant, low concentrations of doxorubicin synergize in vitro and in vivo with DCA to further enhance p53 activation and to block tumor progression. Leukemia cell lines and primary leukemic cells containing mutant p53 are resistant to the above-described combination approach. However, DCA synergized with the Hsp90 inhibitor 17-AAG to specifically eliminate these cells. Our studies strongly indicate that depending on the p53 status, different combination therapies would provide better treatment with decreased side effects in hematological cancers.

Domaines

Hématologie Cancer
Fichier principal
Vignette du fichier
IRMB 35_p33_The presence of wild type p53 in hematological cancers_oncotarget-06-19228.pdf (7.93 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

inserm-01868552 , version 1 (05-09-2018)
inserm-01868552 , version 2 (20-01-2021)

Licence

Paternité

Identifiants

Citer

Nerea Allende-Vega, Ewelina Krzywinska, Stefania Orecchioni, Nuria Lopez-Royuela, Francesca Reggiani, et al.. The presence of wild type p53 in hematological cancers improves the efficacy of combinational therapy targeting metabolism. Oncotarget, 2015, 6 (22), pp.19228-45. ⟨10.18632/oncotarget.4653⟩. ⟨inserm-01868552v2⟩
206 Consultations
170 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More